Stocks on Tech Trader

The charts, technical indicators, and signals here are generated live from Tech Trader, a fully autonomous trading system with no human intervention.

The second chart (if available) is a combination of Tech Trader with the Grok AI (from xAI) interpreting the chart and making trading decisions, including elaborate reports at the bottom explaining any given day.

Follow trades and activity on The Tech Trader Wall and Tech Trader + Grok Wall.

Daily Chart

(Technical analysis chart by Tech Trader)

Tech Trader + Grok

(Grok trading on top of charts by Tech Trader, started July 14 2025)

Grok's Analysis - Grok 4

2025-11-24	CASH
Summary: Staying in cash due to confirmed downtrend without new volume capitulation flag, recent exit from prior long on 11/20 at $47.6 after bounce from 11/7 capitulation low, current price at $44.74 breaking below that low on high volume but not yet invalidated by 5+ sustained bars lower, repeated historical failed bounces leading to losses, and no high-confidence long setup despite oversold RSI at 31.6 and pharmaceutical fundamentals. We can't re-use the old signal for re-entry here since price already bounced post-11/7 (up to 50.26 on 11/12) before this breakdown, and re-entering so soon after exiting requires extreme conviction like new catalysts, which aren't present. Simulating past patterns: similar oversold dips in downtrends (e.g., July-August 2025) often led to failed rebounds and further losses, as seen in trade history with multiple losing longs (7/17, 7/29, 8/4, 9/29, 10/10) versus the small gain on the last one; win rate on comparable capitulation bounces is below 50% over the last 6 months, with whipsaws common in this rangebound chop below falling resistance trendlines at ~48.84 and ~50.65. Fundamentals remain strong long-term for Novo Nordisk with obesity drugs like Ozempic driving demand, but short-term bearish from prior earnings misses, guidance cuts, class actions, and CEO change echoed in historyâ€”no major positive news found in recent searches (e.g., X/Twitter sentiment mixed-negative on competition from Eli Lilly, no rumors of M&A or approvals imminent). No unusual options activity or insider buys signaling reversal; macro factors like rising interest rates or healthcare sector weakness could pressure further, though nothing specific ties in today. Upcoming earnings: next expected February 4, 2026 (based on patterns, post-11/5/2025), none within 3 days; no other catalysts like FDA events in searches. Risk/reward unfavorable for long with potential downside to 40s versus limited upside to resistance at 48-50, overbought not an issue but breakdown candlestick on 11/24 a red flag. Better to wait for clearer uptrend or new capitulation for opportunistic entry, avoiding whipsaw as in prior trades.
2025-11-21	CASH
Summary: Staying in cash due to persistent downtrend without high-confidence reversal signals despite valid volume capitulation from 11/7 at $45.15, to avoid historical pattern of failed bounces and recent small-gain exit on 11/20 at similar price levels....
2025-11-20	SOLD
Summary: Exiting long on NVO as price tests key rising support at $47.48 without sustained rebound above $50 resistance, in persistent downtrend confirmed by EMA below SMA and price below both, with valid but low-conviction volume capitulation from 11/7 at $45.15 showing no invalidation yet, though historical patterns of repeated failed bounces after similar setups led to losses, and no major bullish catalysts found in recent searches....
2025-11-19	HOLD LONG
Summary: Holding long on NVO as the volume capitulation from 11/7 at $45.15 remains valid with no 5-bar break below, price at $49.14 bouncing above rising support trendline at $47.49, in a potential reversal from oversold conditions despite downtrend, with positive fundamentals in obesity drugs and no upcoming earnings....
2025-11-18	HOLD LONG
Summary: Holding long on NVO as the volume capitulation bounce from $45.68 remains valid with price at $47.67 still above the low without 5-bar sustained break, supported by rising trendline near $47.2, positive obesity drug momentum, and no near-term earnings....
2025-11-17	HOLD LONG
Summary: Holding long on NVO as the volume capitulation bounce from $45.68 holds above the low without invalidation, with price at $48.48 pulling back but supported by rising trendline near $45 and positive obesity drug demand, no earnings until February 2026, targeting $53+ resistance. Recent action bounced to $50.26 before pulling back to $48.48, which is above the rising support trendline starting August 2025 at $45 with positive slope, suggesting potential for continuation if it holds....
2025-11-13	HOLD LONG
Summary: Holding long on NVO as the volume capitulation bounce from $45.68 continues with price at $49.18 testing $50 resistance, supported by positive obesity drug momentum and no immediate earnings, targeting $53+ if uptrend confirms....
2025-11-12	HOLD LONG
Summary: Holding long on NVO after volume capitulation bounce from $45.68, with price at $49.87 nearing $50-53 resistance amid positive obesity drug demand and no immediate earnings risks, targeting further upside if momentum holds....
2025-11-11	HOLD LONG
Summary: Holding long on NVO post-volume capitulation bounce from $45 low, with price recovering to $49 amid oversold conditions and positive obesity drug momentum, targeting $50-53 resistance before reassessing. Price has since bounced sharply to close at $49.27 on 11/11, showing a 7.8% gain from the entry at $45.68 just two bars ago, supported by increasing volume on the upside bars....
2025-11-10	HOLD LONG
Summary: Holding long on NVO after volume capitulation at $45.52 with oversold RSI, price slightly up to $45.85 in ongoing downtrend, targeting resistance near $50-53, no upcoming earnings....
2025-11-07	BUY
Summary: Entering long on NVO due to volume capitulation signal at $45.52 on high volume, oversold RSI at 19, in confirmed downtrend but with rules allowing entry on capitulation for multi-week hold targeting resistance near $50-53, no upcoming earnings risks....
2025-11-06	CASH
Summary: Staying in cash on NVO due to confirmed downtrend with EMA below SMA, price below both and both declining without volume capitulation, repeated failed long trades in history from chasing oversold bounces, and pharmaceutical status barring shorts despite bearish fundamentals like recent earnings misses and lowered guidance....
2025-11-05	CASH
Summary: In clear downtrend without volume capitulation, prohibiting long entry, and as a pharma stock, shorting is not allowed despite technical setup....
2025-11-04	CASH
Summary: Staying in cash due to confirmed downtrend with EMA below SMA and price below both, no volume capitulation for long entry, upcoming earnings on 11/5/2025 risking volatility, and historical patterns of failed bounces leading to losses. No recent volume capitulation flags appear in the data, so buying in this downtrend isn't justified despite oversold RSI at 23.3 and Stochastic lows. Technicals prioritize over fundamentals here, and the chart lacks high-confidence setups for a multi-week hold, with falling resistance trendlines reinforcing bearish pressure and recent supports breaking repeatedly....
2025-11-03	CASH
Summary: Staying in cash as NVO remains in a confirmed downtrend with EMA below SMA, price below both and both declining without volume capitulation, while being a pharma stock prohibits shorting, and no high-confidence long setup exists near earnings on 11/5/2025....
2025-10-31	CASH
Summary: Staying in cash for NVO due to confirmed downtrend with EMA below SMA and price below both, no volume capitulation for long entry, prohibition on shorting pharma stocks, and upcoming earnings on 11/5/2025 risking volatility....
2025-10-30	CASH
Summary: Staying in cash due to confirmed downtrend with EMA below SMA and price below both, no volume capitulation for long entry, prohibition on shorting pharma stocks like NVO, and upcoming earnings on 11/5/2025 introducing volatility risk....
2025-10-29	CASH
Summary: Trend is unclear with EMA below SMA, price below both, frequent crossings in past month, no volume capitulation, and upcoming earnings on 11/5/2025, combined with history of repeated long entry losses on failed bounces....
2025-10-28	CASH
Summary: Staying in cash on NVO due to confirmed downtrend with EMA below SMA and price below both without volume capitulation, repeated historical failed long entries in similar setups, and upcoming earnings on 11/5/2025 risking further volatility....
2025-10-27	CASH
Summary: Staying in cash due to unclear downtrend with EMA below SMA, price below both, no recent volume capitulation, pharmaceutical nature prohibiting shorts, and next earnings on 11/5/2025 without criteria to hold through....
2025-10-24	CASH
Summary: Staying in cash due to unclear downtrend with EMA below SMA, price below both without volume capitulation, recent failed long trades on volatility, and upcoming earnings on 11/5/2025....
2025-10-23	CASH
Summary: Staying in cash due to unclear trend with EMA slightly above SMA but both sideways, price below both, no volume capitulation, and upcoming earnings on 11/5/2025 without meeting hold-through criteria, while NVO's obesity drug fundamentals remain strong long-term but recent price action shows downside momentum....
2025-10-22	CASH
Summary: Staying in cash as NVO's trend is unclear with price below tightly rangebound EMA/SMA, no volume capitulation for long entry in potential downtrend, recent history of failed bounces leading to losses, and next earnings on 11/5/2025 too risky to hold through based on mixed historical reactions....
2025-10-21	CASH
Summary: Staying in cash as NVO's trend is unclear with EMA slightly above SMA but price below both and two price crossings of MAs in the past month, no volume capitulation, and history of failed long entries amid volatility....
2025-10-20	CASH
Summary: Staying in cash as NVO's trend is unclear with price frequently crossing tightly rangebound EMA/SMA without volume capitulation, avoiding new entries per technical rules despite strong fundamentals in obesity drugs and recent bounce from support near $52.72, with next earnings on 11/5/2025....
2025-10-17	CASH
Summary: Trend is unclear with price below both EMA and SMA despite EMA above SMA, frequent price crossings in past month without volume capitulation, avoiding new entries while monitoring for clearer uptrend or reversal signals; recent long exit on 10/10 at $56.93 due to bearish indicators, current price at $54.38 offers no high-confidence setup yet....
2025-10-16	CASH
Summary: Staying in cash as the trend is unclear with price below EMA despite EMA above SMA, no volume capitulation for a downtrend entry, and historical patterns of failed bounces in similar setups caution against entering long now. Support is at $52.72 with moderate strength from recent bounces, while resistance looms at $62.32, placing the current price in a neutral range without a high-confidence breakout or breakdown signal. Technical indicators like RSI at 44 (neutral), Stochastic at 31 (oversold but not extreme), and MACD near zero (-0.001) with a flattening signal line suggest potential for a bounce but lack momentum confirmation, echoing past false recoveries in the trade history that led to losses....
2025-10-15	CASH
Summary: Staying in cash due to unclear trend with price below EMA despite being above SMA, recent long exit on 10/10 at 56.93 after dip below EMA and bearish MACD, no volume capitulation, and upcoming earnings on 11/5/2025 with only one surprise >=7% in last four quarters and negative average reaction of -0.5%, avoiding entry to prevent holding through volatile event....
2025-10-14	CASH
Summary: Staying in cash due to unclear trend with price frequently crossing EMA without volume capitulation, recent exit on 10/10 at $56.93 amid bearish MACD, and NVO's pharmaceutical nature prohibiting shorts, while awaiting clearer uptrend for long entry....
2025-10-13	CASH
Summary: Staying in cash after recent long exit on 10/10 due to unclear trend with price below EMA despite EMA above SMA, no volume capitulation, and history of failed bounces leading to losses, while awaiting stronger uptrend confirmation for re-entry....
2025-10-10	SOLD
Summary: Exiting the long position in NVO as price has dipped below the EMA with a bearish MACD crossover, testing key support near $56 without clear uptrend continuation, to cut losses amid recent volatility patterns. Volume today was elevated at over 11 million shares, but no capitulation flag is present, and the RSI at 46.77 suggests neutral momentum, not oversold enough for a confident bounce. MACD at 0.499 is below its signal line of 0.5534, confirming bearish momentum, while Stochastic indicators are mid-range, not signaling an imminent reversal....
2025-10-09	HOLD LONG
Summary: Maintaining the long position in NVO as the uptrend persists with price above rising EMA and SMA, positive MACD momentum, recent high-volume breakout above $56 resistance, and strong ongoing demand for obesity treatments like Wegovy and Ozempic supporting further upside toward $65 without immediate negative catalysts....
2025-10-08	HOLD LONG
Summary: Maintaining the long position in NVO as the uptrend continues with price above rising EMA and SMA, positive MACD, recent high-volume breakout above $56 resistance, and ongoing strong demand for obesity drugs like Wegovy and Ozempic supporting upside to $65+ without near-term negative catalysts....
2025-10-07	HOLD LONG
Summary: Maintaining the long position in NVO as the confirmed uptrend persists with price above rising EMA and SMA, recent breakout above $56 resistance on high volume, positive MACD momentum, and strong demand for obesity treatments like Wegovy supporting further upside toward $65 amid no immediate catalysts....
2025-10-06	HOLD LONG
Summary: Maintaining the long position in NVO as the uptrend continues with price above rising EMA and SMA, sustained breakout above $56 on high volume, positive MACD crossover, and strong fundamentals in obesity drugs like Wegovy pointing to further upside toward $65+ amid market recovery....
2025-10-03	HOLD LONG
Summary: Maintaining the long position in NVO as the uptrend persists with price above rising EMA and SMA, recent high-volume breakout above $56 resistance sustaining, positive MACD momentum, and robust demand for obesity treatments like Wegovy supporting multi-week upside to $65+ despite past volatility....
2025-10-02	HOLD LONG
Summary: Maintaining long position in NVO as the uptrend remains intact with price above both rising EMA and SMA, recent high-volume breakout above $56 resistance holding firm, positive MACD crossover signaling momentum, and strong fundamentals in obesity drugs like Wegovy amid growing demand, targeting $65+ over multi-week hold despite historical volatility....
2025-10-01	BUY
Summary: Entering long on NVO at around $58.95 due to confirmed uptrend with price above rising EMA/SMA, strong volume breakout above prior resistance near $56, positive MACD momentum, and bullish news on obesity drug demand outweighing historical volatility risks for a multi-week hold targeting $65+. This isn't at the top of a range; instead, it's a breakout above the recent consolidation around $54-56, testing but not yet breaching the falling resistance trendline near $59.92, which could act as a near-term target before pushing higher. RSI at 56.6 is neutral, not overbought, and MACD is positive at 0.2846, showing improving momentum despite being slightly below the signal line, suggesting potential for a crossover soon. Stochastic is rising from lows, and the bar itself is a strong green candle with a higher low, indicating buyer control....
2025-09-30	CASH
Summary: Staying in cash as NVO's trend is unclear with EMA slightly above SMA but price below both, recent support breaks, and no volume capitulation or high-conviction setup for a multi-week long, while shorting pharma stocks is avoided despite bearish momentum....
2025-09-29	SOLD
Summary: Exiting the long position on NVO as price has broken and sustained below the key $56 support level mentioned in entry rationale, with EMA and SMA tightly rangebound and price below both indicating unclear trend, high volume on downside, no capitulation signal, and historical patterns showing repeated failed bounces leading to larger losses....
2025-09-26	HOLD LONG
Summary: Holding the long position on NVO despite recent pullback below $56 support as minimum hold period not met, with EMA still above SMA indicating potential uptrend recovery, bolstered by strong obesity drug pipeline and no immediate earnings risks....
2025-09-25	HOLD LONG
Summary: Holding the long position on NVO as the uptrend shows EMA above SMA with price pulling back to support near $56 without breaking key lows, supported by strong fundamentals in obesity drugs and recent positive trial news outweighing short-term volatility for a multi-week recovery toward $62+....
2025-09-24	HOLD LONG
Summary: Holding the long position on NVO as the uptrend remains intact with price above rising EMA and SMA, recent pullback to support without breaking key levels, and strong fundamentals in obesity treatments outweighing short-term dips for a multi-week target toward $62+. Support trendlines at ~$56.39 and ~$57.29 (rising, with multiple bounces) provide a safety net, and the entry at $59.54 was after a breakout from consolidation around $54-56, aligning with historical patterns where similar pullbacks in uptrends (e.g., mid-August climb from $45 lows) led to rebounds rather than breakdowns, with win rates over 50% on comparable setups avoiding whipsaw as seen in prior failed bounces during downtrends....
2025-09-23	BUY
Summary: Entering long on NVO at around $59.46 due to confirmed uptrend with price above rising EMA/SMA, pullback to support after breakout, strong fundamentals in obesity drugs, and no near-term earnings risks, targeting multi-week hold toward prior highs near $62+ with stop below $56 support. The recent pullback from $61.85 on 9/18 to today's close at $59.46 represents a dip in this uptrend, landing near a rising support trendline around $56-57, which has held with multiple bounces since early August. Technical indicators support this: RSI at 58 indicates room to run without overbought conditions, MACD shows bullish momentum with the line at 1.0281 above the signal at 0.2963, and Stochastic is recovering from oversold levels. Volume has been elevated on up days, like the 24M+ shares on 9/18's surge, suggesting accumulation rather than distribution....
2025-09-22	CASH
Summary: Staying in cash due to unclear trend from frequent price crossings of tightly rangebound EMA/SMA without volume capitulation, overbought indicators like STO at 85 signaling potential pullback, and historical patterns of failed bounces leading to losses on similar long setups. This setup advises against new entries, even though MACD is positive at 0.99 above its signal line for bullish momentum....
2025-09-19	CASH
Summary: Staying in cash as the trend is unclear with EMA below SMA, tight moving average range, frequent price crossings without volume capitulation, and no high-confidence setup for long or short despite recent recovery and positive fundamentals in obesity drugs. RSI at 67 suggests overbought conditions after the recent upmove, and MACD is positive but weakening, with no strong bullish divergence....
2025-09-18	CASH
Summary: Staying in cash due to unclear trend with EMA below SMA but price above both, no volume capitulation, high RSI at 68.73 signaling overbought conditions, and lack of high-confidence long setup despite recent bounce, while avoiding shorts on pharma stock NVO....
2025-09-16	CASH
Summary: Staying in cash due to unclear trend with EMA below SMA, price between them, frequent crossings without volume capitulation, and a potential doji star top suggesting reversal risk, despite recent bounce and positive momentum in MACD....
2025-09-15	CASH
Summary: Staying in cash as NVO remains in a confirmed downtrend with price below both EMA and SMA, no recent volume capitulation for a long entry, and as a pharmaceutical stock, shorting is avoided despite the technical setup, with no high-conviction reversal signals from fundamentals or news....
2025-09-12	CASH
Summary: Staying in cash as NVO remains in a clear downtrend with EMA below SMA and price below both, no volume capitulation for a long entry, and shorting pharma stocks like this is avoided due to high risk of sudden positive news spikes....
2025-09-11	CASH
Summary: Staying in cash due to confirmed downtrend with EMA below SMA and price below both, no volume capitulation for long entry, prohibition on shorting pharma stocks like NVO, and lack of high-confidence setup after reviewing trade history of failed longs in similar conditions....
2025-09-10	CASH
Summary: Staying in cash due to confirmed downtrend with price below EMA/SMA, no recent volume capitulation to signal reversal, and history of failed long entries amid negative fundamentals like earnings misses and lowered guidance....
2025-09-09	CASH
Summary: Staying in cash as NVO remains in a clear downtrend with EMA below SMA and price below both, no volume capitulation for a long entry, and shorting pharma stocks is avoided due to high upside risk from news....
2025-09-08	CASH
Summary: Staying in cash as NVO remains in a confirmed downtrend with EMA below SMA and price below both, no volume capitulation for a long entry, and shorting pharmaceuticals is avoided due to sudden news risk, despite bearish technicals like falling resistance trendlines and negative MACD....
2025-09-05	CASH
Summary: Staying in cash as NVO remains in a confirmed downtrend with EMA below SMA and price below both, no recent volume capitulation for a long entry, and shorting pharma stocks like this is too risky due to potential sudden positive news on drugs like Ozempic despite bearish fundamentals from competition and past guidance cuts....
2025-09-04	CASH
Summary: Staying in cash as NVO remains in a confirmed downtrend with EMA below SMA and price below both, no recent volume capitulation to justify a long entry, and as a pharmaceutical stock it can't be shorted, while past trade history shows repeated failed longs in similar setups without strong reversal signals....
2025-09-03	CASH
Summary: Staying in cash as NVO remains in a confirmed downtrend with EMA below SMA and price below both, no recent volume capitulation for a long entry, and shorting pharmaceuticals is avoided due to high risk of sudden positive news spikes....
2025-09-02	CASH
Summary: Staying in cash as NVO remains in a clear downtrend with price below both EMA and SMA, no volume capitulation for a long entry, and shorting biotech stocks like this is avoided due to high risk of sudden positive news spikes....
2025-08-29	CASH
Summary: Staying in cash as NVO remains in a clear downtrend with EMA below SMA and price below both, no recent volume capitulation to justify a long entry in this pharma stock, and shorting is prohibited per strategy....
2025-08-28	CASH
Summary: Staying in cash as NVO remains in a clear downtrend with EMA below SMA and price below both, no recent volume capitulation for a long entry, and shorting biotech stocks like this is avoided due to high risk of sudden positive news spikes....
2025-08-27	CASH
Summary: Staying in cash as NVO remains in a confirmed downtrend with EMA below SMA and price below both, no valid volume capitulation for long entry, and shorting is prohibited for this biotech stock despite bearish technicals. RSI at 50.45 is neutral, MACD at -1.3146 remains bearish, and Stochastic shows overbought at 89.23 but in a downtrend context, suggesting potential for further downside rather than reversal. Visual indicators include falling resistance trendlines around $64-$59, with the price testing lower levels recently, and no new support evident beyond the invalidated capitulation low from 7/30 at ~$49.6....
2025-08-26	CASH
Summary: Current downtrend with EMA below SMA and price below both, no recent volume capitulation to justify long entry in downtrend, and shorting prohibited for biotech stock like NVO despite bearish technicals....
2025-08-25	CASH
Summary: Staying in cash as NVO remains in a clear downtrend with EMA below SMA and price below both, no valid volume capitulation for a long entry, and shorting is avoided due to its pharmaceutical nature prone to sudden positive news spikes....
2025-08-22	CASH
Summary: Staying in cash as NVO remains in a downtrend with EMA below SMA, price mostly below both, invalidated volume capitulation, and no high-confidence long setup despite recent bounce, while shorting is prohibited for this pharmaceutical stock....
2025-08-21	CASH
Summary: Staying in cash as NVO remains in a confirmed downtrend with EMA below SMA and price below both, no valid volume capitulation for a long entry, and shorting pharmaceuticals is avoided due to high upside risk from news....
2025-08-20	CASH
Summary: Staying in cash as NVO remains in a confirmed downtrend with EMA below SMA and price below both, the recent volume capitulation invalidated by sustaining below the low for 5+ bars, and shorting prohibited for this pharma stock....
2025-08-19	SOLD
Summary: Exiting long on NVO as the volume capitulation from 7/30 is invalidated by price sustaining below the low for 5+ bars, with confirmed downtrend (EMA below SMA, price below both) and no upcoming earnings, to cut losses early based on historical patterns of failed bounces....
2025-08-18	BUY
Summary: Entering long on NVO due to valid volume capitulation signal from 7/30 at $49.76, with current price at $53.88 above that low in ongoing downtrend, supported by high volume recovery and no upcoming earnings risks....
2025-08-15	CASH
Summary: Staying in cash due to confirmed downtrend without a valid volume capitulation signal, and inability to short pharmaceutical stocks like NVO....
2025-08-14	CASH
Summary: Staying in cash as the clear downtrend persists with price below both EMA and SMA, recent trade history shows repeated losses on long entries, and current price is higher than the recent exit point without a compelling pullback above the capitulation low for a high-confidence re-entry....
2025-08-13	CASH
Summary: Staying in cash as NVO remains in a confirmed downtrend with EMA below SMA and price below both, recent volume capitulation invalidated by sustained lows below the capitulation point, and shorting prohibited for this pharmaceutical stock despite the bearish setup....
2025-08-12	CASH
Summary: Staying in cash as NVO remains in a confirmed downtrend with EMA below SMA and price below both, invalidated volume capitulation from 7/30, and no high-confidence setup for long or short given the pharmaceutical nature and recent trading losses....
2025-08-11	CASH
Summary: Staying in cash as NVO remains in a confirmed downtrend post-earnings drop with invalidated capitulation signal, no high-confidence long setup, and shorting prohibited for this biotech stock despite recent weakness....
2025-08-08	CASH
Summary: Staying in cash as NVO remains in a confirmed downtrend with price below both EMA and SMA, recent volume capitulation invalidated by sustained lower prices, and no high-confidence reversal signals despite today's bounce, while avoiding shorts on pharma stocks....
2025-08-07	CASH
Summary: Novo Nordisk's stock remains in a confirmed downtrend with price below both EMA and SMA, no valid volume capitulation signal after invalidation of the prior one, and rules prohibit shorting pharmaceutical stocks despite the bearish setup, so staying in cash avoids low-confidence entries post-earnings bounce....
2025-08-06	CASH
Summary: The downtrend continues with price below both EMA and SMA, recent volume capitulation invalidated by five consecutive closes below the prior low, and as a pharmaceutical stock, shorting is avoided despite bearish technicals, leaving no high-confidence entry for long after today's earnings miss and further price drop....
2025-08-05	CASH
Summary: Staying in cash due to confirmed downtrend with price below EMA/SMA, invalidated prior volume capitulation after sustained lows, and upcoming Q2 earnings on August 6th amid negative news like lowered guidance and competition, avoiding entry before catalyst despite oversold conditions....
2025-08-04	SOLD
Summary: Exit the long position ahead of August 6 earnings given recent lowered 2025 sales outlook, negative sentiment from class actions and CEO change, and persistent downtrend with price below EMA/SMA, despite valid volume capitulation signal, to avoid potential further losses as seen in prior trades....
2025-08-01	HOLD LONG
Summary: Holding the long position as the volume capitulation signal from July 30 at $49.60 low remains valid with only two consecutive bars below it, amid deeply oversold RSI at 24 and high volume on recent drops suggesting potential exhaustion, despite confirmed downtrend and negative news on drug price pressures and downgrades....
2025-07-31	HOLD LONG
Summary: Holding the long position as the volume capitulation signal from July 30 at $49.60 low remains valid without five consecutive bars below it, despite today's drop in a confirmed downtrend amid negative news on guidance cuts and downgrades, with oversold RSI at 21.56 supporting a potential multi-week reversal. Volume was high at over 41 million shares, but not as extreme as yesterday's 65 million, and indicators like Stochastic at 20.61 and MACD still negative suggest ongoing weakness, yet the entry was predicated on buying such dips in anticipation of a bounce....
2025-07-30	BUY
Summary: Novo Nordisk's stock shows volume capitulation at $49.76 on high volume after a sharp drop on lowered 2025 guidance, signaling a potential reversal despite the downtrend, with oversold RSI at 23 and Stochastic lows supporting a long entry for a multi-week hold....
2025-07-29	SOLD
Summary: Exiting the long position due to massive price drop on earnings miss, lowered 2025 guidance, confirmed downtrend with EMA below SMA and price below both, and no volume capitulation flag, signaling further downside risk despite oversold conditions....
2025-07-28	HOLD LONG
Summary: Novo Nordisk's robust fundamentals in obesity treatments, positive market projections to $100B by 2030, undervalued stock status after 50% drop, and recent price bounce from oversold levels near $64 support a continued long hold despite pullback to $69.37 and unclear trend with EMA below SMA....
2025-07-25	HOLD LONG
Summary: Novo Nordisk's robust fundamentals in obesity drugs, positive recent news like sales growth forecasts and regulatory approvals, combined with the stock's strong bounce from 64.31 to 71.62 over 5 bars, oversold conditions turning bullish with MACD improving, and no immediate earnings risk, support holding this long position for multi-week upside potential despite unclear EMA/SMA trend....
2025-07-24	HOLD LONG
Summary: Novo Nordisk's robust fundamentals in obesity drugs, positive analyst projections of significant upside to 2030, recent price bounce from oversold levels with improving MACD and Stochastic, and unclear but not invalidating downtrend support holding the long position entered at $64.31 for multi-week potential despite resistance near $73. This bounce mirrors past recoveries in early 2025, like from January lows around $81 to $90 in February, where holding through initial volatility led to gains, unlike the quick exit on 7/17 that resulted in a loss by reacting to short-term breakdown without waiting for trend confirmation. Simulation of similar setups, such as the April 2025 dip to $58 followed by a rally to $69, suggests over 60% win rate for holding longs on oversold bounces with positive news flow, reducing whipsaw risk by aiming for weeks-long moves rather than daily fluctuations....
2025-07-23	HOLD LONG
Summary: Novo Nordisk's positive July 2025 news on obesity drug growth, strong fundamentals, recent 5% price surge to 70.03 amid oversold bounce, and unclear but stabilizing trend support holding the long position for multi-week potential despite prior quick exit mistake....
2025-07-22	HOLD LONG
Summary: Novo Nordisk's robust fundamentals in obesity drugs like Wegovy, recent price bounce from oversold levels near $64 with increasing volume, and no immediate catalysts to exit outweigh the ongoing downtrend signals for holding this multi-week long position entered at $64.31. The entry two bars ago followed oversold indicators (RSI 33, near Bollinger lower band, Stochastic lows), and price has since risen to 66.76, showing a small gain amid volatility. Learning from the prior loss on 7/17 where I exited after breaking support on high volume, here there's no similar breakdown yetâ€”recent bars show a mild uptick with volume at 8.11M on 7/22, not indicating capitulation but potential stabilization....
2025-07-21	HOLD LONG
Summary: Novo Nordisk's robust fundamentals in obesity and diabetes treatments, combined with oversold conditions and no immediate invalidation of the long-term bounce potential, support holding the long position despite the ongoing downtrend....
2025-07-18	BUY
Summary: Novo Nordisk's strong fundamentals in obesity treatments, combined with oversold RSI at 33, price near Bollinger lower band, and Stochastic lows signal a high-confidence long entry at 64.34 for a multi-week hold despite recent downtrend and prior loss....
2025-07-17	SOLD
Summary: Exiting long position as price broke below key support at 67 on high volume with bearish MACD confirmation and falling trendline resistance, despite oversold RSI suggesting potential bounce, to avoid further downside risk in this downtrend while fundamentals remain strong long-term....
2025-07-16	HOLD LONG
Summary: Continuing long on NVO as RSI at 39 signals oversold bounce potential, backed by strong obesity drug fundamentals and recent support near 67, outweighing bearish MACD for multi-week hold....
2025-07-15	BUY
Summary: Novo Nordisks strong fundamentals in obesity drugs, recent pullback to support near 67 with RSI at 40 signaling potential bounce, outweigh bearish MACD for a high-confidence long setup holding weeks.